Close Menu

NEW YORK – Natera reported after the close of the market on Wednesday that its fourth quarter 2019 revenues grew 24 percent year over year, while full-year revenues climbed 17 percent.

2019 "was clearly a transformational year for us across all focus areas," said Steve Chapman, the firm's CEO, on a conference call to discuss the financial results. "We delivered financial results above the top of our previous guidance."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.